摘要
目的探讨CYP3A4基因多态性对冠心病患者阿托伐他汀调脂效应及预后的影响。方法选择我院2012年9月至2014年10月诊治的183例冠心病患者为研究对象,通过PCR-RFLP方法对CYP3A4基因型进行测定。指导患者口服20 mg阿托伐他汀调脂药物,用药1年后比较治疗后CYP3A4不同基因型患者的血脂变化。另外随访1-1.5年,观察和记录随访期间不同基因型患者的生存情况。结果 TT基因型与TC基因型[（-42.54±1.12）%vs.（-25.00±1.06）%]、CC基因型[（-42.54±1.12）%vs.（-11.03±1.06）%]LDL水平变化比较差异显著（P〈0.05）。另外,随访1-1.5年,TT基因型、TC基因型、CC基因型患者生存率分别为95.35%、92.31%、86.11%,三组比较差异无统计学意义（P〉0.05）。结论 CYP3A4基因多态性可影响阿托伐他汀调脂效应,特别是LDL水平。同时CYP3A4三种不同基因型的冠心病临床预后差异不明显。
Objective To investigate the impact of CYP3A4 gene polymorphism on lipid regulating effects and prognosis of atorvastatin in patients with coronary artery disease. Methods 183 patients with coronary heart disease were selected, and the CYP3A4 genotype was detected by PCR-RFLP. All patients were given 20 mg of atorvastatin for one year, and the changes in plasma lipids between patients with different CYP3A4 genotype were compared. All cases were followed-up for 1 - 1.5 years to observe the survival situations. Results There were statistically significant differences in LDL levels between TT genotype and TC genotype, TT genotype and CC genotype, both P〈0.05.The survival rates during follow-up of TT genotype, TC genotype and CC genotype were 95.35%, 92.31% and 86.11% respectively, without significant difference（P〉0.05）. Conclusions CYP3A4 gene polymorphism influences the lipid regulating effects of atorvastatin, especially the level of LDL. Three different CYP3A4 genotypes have the similar impact on clinical prognosis of coronary heart disease.
出处
《临床医学工程》
2015年第1期71-72,共2页
Clinical Medicine & Engineering
